Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: The multidrug resistance protein 1 (MRP1) is expressed in human breast cancer cells and may contribute to the clinical drug resistance of breast cancer patients. Therefore, we determined the impact of MRP1 expression on the clinical outcome of adjuvant therapy in patients with early-stage breast cancer. Patients and Methods: Immunostaining for MRP1 was performed on tissue sections from 516 premenopausal, hormone receptor-positive breast cancer patients with stage I and II disease. Statistical analyses were performed to assess the effect of MRP1 expression on survival and to test for interaction between MRP1 expression and treatment. Results: MRP1 expression independently predicted shorter relapse-free survival (RFS) and overall survival (OS) in patients treated with cyclophosphamide, methotrexate, and fluorouracil (CMF; RFS: hazard ratio [HR] = 1.48; 95% CI, 1.16 to 1.88; P = .002; OS: HR = 1.82; 95% CI, 1.10 to 3.01; P = .02), but it did not predict shorter RFS and OS in patients who received tamoxifen plus goserelin (RFS: HR = 0.99; 95% CI, 0.74 to 1.31; P = .9; OS: HR = 0.68; 95% CI, 0.40 to 1.15; P = .1). Tests for interaction between MRP1 expression and treatment were statistically significant for both RFS (P = .04) and OS (P = .006). Conclusion: Our data suggest that MRP1 expression plays an important role in the clinical resistance to adjuvant CMF chemotherapy but does not seem to affect response to adjuvant endocrine treatment with tamoxifen plus goserelin. Thus, MRP1 may be a useful marker for the selection of patients with early-stage breast cancer for the appropriate adjuvant therapy after prospective confirmatory evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 1×
“The multidrug resistance protein 1 (MRP1), also called ABCC1, is another member of the ABC transporter family.(4) Overexpression of this protein in tumor cells confers resistance to various anticancer drugs, such as anthracyclines or methotrexate,(4-7) which are drugs that are part of the chemotherapy regimens current…”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 2×
“The ABC transporter MRP1 is one of the most interesting molecular markers associated with resistance to various anticancer drugs.(1,2) In the current study, we have examined MRP1 expression in a large, homogenous, and well-defined patient population consisting of premenopausal, hormone receptorpositive breast cancer p…”
Background
Cited by
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
“, and its prognostic implication in chronic lymphocytic and promyelocytic leukaemia, non-small-cell lung cancer (NSCLC) and breast cancer remains controversia”
BackgroundDeeley, R. G., Westlake, C., & Cole, S. P. C. (2006) · Physiological Reviews · doi:10.1152/physrev.00035.2005 · Cited by 761
“The results of these investigations have recently been supported by a larger analysis of MRP1 expression in over 500 premenopausal women with early-stage breast cancer (124).”
ResultABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399
“This tripeptide thiol has a major role in the protection of cells from drug-induced oxidative stress by mediating cellular detoxification of drugs and their extrusion via multidrug resistance proteins (Haimeur et al., 2002; Filipits et al., 2005; Yang et al., 2006; Yadav et al., 2007).”
BackgroundMechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
Coley, H. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.007 · Cited by 351
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., & Papadimitriou, C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.011 · Cited by 261
Liu, X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-7647-4_2 · Cited by 254
Trop2: A possible therapeutic target for late stage epithelial carcinomas
Cubas, R., Li, M., Chen, C., & Yao, Q. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.001 · Cited by 192
Resistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response
Mellor, H. R., & Callaghan, R. (2008) · Pharmacology · doi:10.1159/000115967 · Cited by 168
Hanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Metadata
- Authors
- Filipits, M., Pohl, G., Rudas, M., Dietze, O., Lax, S., Grill, R., Pirker, R., Zielinski, C. C., Hausmaninger, H., Kubista, E., Samonigg, H., & Jakesz, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-20
- Volume
- 23
- Issue
- 6
- Pages
- 1161-1168
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154415145
- Cited by
- 104
- References
- 3
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.